Skip to main content

Table 9 Antibiotic resistance in Gram–negative isolates

From: Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country

 

Frequency

Ampicillin

Amoxicillin–clavulanate

Piperacillin

Piperacillin tazobactam

Imipenem

Meropenem

Ertapenem

Cefotaxime

Cefepime

 Gram-negative bacteria

22

Resistant isolates (% of tested)

 Klebsiella pneumoniae

5

5 (100)

3 (75)

3 (60)

1 (20)

1 (20)

1 (20)

3 (60)

2 (40)

 ESBL-E. coli

3

3 (100)

2 (66.7)

1 (33.3)

0

0

0

3 (100)

3 (100)

 Non-ESBL E. coli

2

0

0

0

0

0

0

0

0

 Neisseria sicca

2

0

0

 Pseudomonas aeruginosa

4

1 (100)

2 (66.7)

1 (25)

3 (75)

2 (66.7)

1 (100)

2 (50)

 Sphingomonas paucimobilis

1

0

0

0

0

 E. fergusonii

1

1 (100)

0

0

0

0

0

0

0

 Acinetobacter baumannii

3

1 (100)

3 (100)

3 (100)

3 (100)

3 (100)

 Pseudomonas stutzeri

1

0

0

0

0

0

 

Ceftriaxone

Ceftazidime

Ciprofloxacin

TMP/SMX

Gentamicin

Tobramycin

Amikacin

Tetracycline

Minocycline

Nitrofurantoin

 Gram-negative bacteria

Resistant isolates (% of tested)

 Klebsiella pneumoniae

2 (50)

3 (60)

3 (60)

2 (40)

0

1 (20)

 ESBL-E. coli

3 (100)

2 (66.7)

2 (66.7)

2 (66.7)

0

0

 Non-ESBL E. coli

0

0

0

0

0

0

0

 Neisseria sicca

0

0

0

0

0

 Pseudomonas aeruginosa

2 (50)

2 (50)

2 (66.7)

2 (66.7)

2 (50)

 Sphingomonas paucimobilis

0

0

0

0

0

 E. fergusonii

0

1 (100)

1 (100)

0

 Acinetobacter baumannii

3 (100)

3 (100)

3 (100)

3 (100)

3 (100)

0

 Pseudomonas stutzeri

0

0

0

0

0

0

  1. ESBL, extended-spectrum beta-lactamase; E. fergusonii, Escherichia fergusoni